Inhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.8% in November

Inhibrx, Inc. (NASDAQ:INBX) saw a large increase in short interest in November. As of November 30th, there was short interest totalling 1,090,000 shares, an increase of 5.8% from the November 15th total of 1,030,000 shares. Based on an average daily volume of 84,700 shares, the short-interest ratio is currently 12.9 days. Currently, 11.0% of the shares of the stock are sold short.

Inhibrx Stock Down 0.9 %

INBX stock opened at $14.62 on Monday. Inhibrx has a one year low of $10.80 and a one year high of $18.95. The firm has a 50-day moving average of $15.38 and a two-hundred day moving average of $14.93.

Insider Activity

In other news, Director Jon Faiz Kayyem acquired 69,686 shares of Inhibrx stock in a transaction on Tuesday, November 19th. The stock was bought at an average cost of $14.23 per share, with a total value of $991,631.78. Following the completion of the purchase, the director now owns 51,093 shares of the company’s stock, valued at $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 22.20% of the company’s stock.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.